DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,109 filers reported holding DANAHER CORPORATION in Q4 2016. The put-call ratio across all filers is 0.26 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $405,390,242 | +10.3% | 1,633,999 | +6.7% | 0.13% | +15.7% |
Q2 2023 | $367,549,347 | +17.6% | 1,531,352 | +23.5% | 0.12% | +11.7% |
Q1 2023 | $312,671,507 | +0.0% | 1,240,440 | +5.4% | 0.10% | -3.7% |
Q4 2022 | $312,527,000 | +32.7% | 1,177,378 | +29.4% | 0.11% | +23.0% |
Q3 2022 | $235,544,000 | -22.5% | 910,035 | -24.2% | 0.09% | -17.9% |
Q2 2022 | $303,797,000 | -23.0% | 1,200,002 | -11.4% | 0.11% | -8.6% |
Q1 2022 | $394,544,000 | -2.9% | 1,354,396 | +8.9% | 0.12% | +3.6% |
Q4 2021 | $406,523,000 | +19.6% | 1,244,000 | +11.5% | 0.11% | +2.8% |
Q3 2021 | $339,831,000 | +0.4% | 1,116,149 | -11.5% | 0.11% | +3.8% |
Q2 2021 | $338,537,000 | +18.3% | 1,261,504 | -0.8% | 0.10% | +10.5% |
Q1 2021 | $286,176,000 | -33.9% | 1,271,408 | -34.7% | 0.10% | -37.9% |
Q4 2020 | $432,635,000 | +9.6% | 1,947,750 | +6.2% | 0.15% | -5.0% |
Q3 2020 | $394,814,000 | +21.9% | 1,833,719 | +0.0% | 0.16% | +15.8% |
Q2 2020 | $323,772,000 | +22.6% | 1,832,857 | -4.0% | 0.14% | 0.0% |
Q1 2020 | $264,057,000 | +0.1% | 1,908,523 | +11.0% | 0.14% | +26.4% |
Q4 2019 | $263,846,000 | +6.4% | 1,719,323 | +0.2% | 0.11% | -0.9% |
Q3 2019 | $247,929,000 | +20.6% | 1,716,450 | +19.4% | 0.11% | +20.7% |
Q2 2019 | $205,556,000 | +20.9% | 1,438,060 | +11.7% | 0.09% | +17.9% |
Q1 2019 | $170,007,000 | +76.3% | 1,287,558 | +37.7% | 0.08% | +62.5% |
Q4 2018 | $96,443,000 | -11.2% | 935,034 | +0.0% | 0.05% | +26.3% |
Q3 2018 | $108,656,000 | -2.9% | 934,900 | -17.5% | 0.04% | -22.4% |
Q2 2018 | $111,859,000 | +1.6% | 1,133,485 | +0.8% | 0.05% | -2.0% |
Q1 2018 | $110,096,000 | +2.0% | 1,124,237 | -3.3% | 0.05% | +2.0% |
Q4 2017 | $107,924,000 | +2.3% | 1,162,599 | -5.5% | 0.05% | -2.0% |
Q3 2017 | $105,501,000 | +23.7% | 1,229,799 | +21.6% | 0.05% | +16.3% |
Q2 2017 | $85,316,000 | -8.2% | 1,011,262 | -6.9% | 0.04% | -10.4% |
Q1 2017 | $92,894,000 | +16.0% | 1,086,043 | +5.6% | 0.05% | +9.1% |
Q4 2016 | $80,047,000 | -7.9% | 1,028,217 | -7.2% | 0.04% | -10.2% |
Q3 2016 | $86,902,000 | -15.2% | 1,108,465 | +9.2% | 0.05% | -18.3% |
Q2 2016 | $102,514,000 | +17.4% | 1,014,738 | +10.2% | 0.06% | +15.4% |
Q1 2016 | $87,339,000 | +9.4% | 920,506 | +7.1% | 0.05% | +10.6% |
Q4 2015 | $79,852,000 | +7.4% | 859,575 | -1.4% | 0.05% | +2.2% |
Q3 2015 | $74,319,000 | +6.7% | 872,000 | +7.2% | 0.05% | +15.0% |
Q2 2015 | $69,656,000 | -3.0% | 813,674 | -3.8% | 0.04% | -2.4% |
Q1 2015 | $71,800,000 | +1.2% | 845,542 | +2.2% | 0.04% | 0.0% |
Q4 2014 | $70,944,000 | +12.7% | 827,612 | -0.1% | 0.04% | +7.9% |
Q3 2014 | $62,969,000 | -26.5% | 828,663 | -23.8% | 0.04% | -25.5% |
Q2 2014 | $85,657,000 | -22.8% | 1,087,896 | -26.5% | 0.05% | -23.9% |
Q1 2014 | $110,999,000 | +15.0% | 1,479,903 | +18.3% | 0.07% | +15.5% |
Q4 2013 | $96,545,000 | +15.2% | 1,250,548 | +3.5% | 0.06% | +5.5% |
Q3 2013 | $83,787,000 | -61.3% | 1,208,672 | -64.7% | 0.06% | -63.3% |
Q2 2013 | $216,745,000 | – | 3,424,033 | – | 0.15% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |